대한의생명과학회지 (Biomedical Science Letters)

  • 제28권4호
  • /
  • Pages.223-228
  • /
  • 2022
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Overview of Utilization of Tumor Markers for Cancer Diagnosis

  • Hong Sung, Kim (Department of Biomedical Laboratory Science, Korea Nazarene University)
  • 투고 : 2022.10.24
  • 심사 : 2022.11.28
  • 발행 : 2022.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

It has well reported that tumor markers have many advantages like minimally invasive, convenient use, low cost but also has many limitations like low sensitivity and specificity, relevance of prognosis, low organ specificity. Although no tumor markers are ideal, many tumor markers are used for cancer diagnosis, treatment monitoring, and surveillance monitoring after treatment. We review the classification and characteristics of tumor markers according cancer types and clinical roles in current times.

키워드

과제정보

This research was supported by Korea Nazarene University Research Fund.

참고문헌

  1. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (remark): Explanation and elaboration. PLoS Med. 2012. 9: e1001216.
  2. Arrieta O, Cacho B, Morales-Espinosa D, Ruelas-Villavicencio A, Flores-Estrada D, Hernandez-Pedro N. The progressive eleation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer. 2007. 7: 28.
  3. Baek AR, Seo HJ, Lee JH, Park SW, Jang AS, Paik SH, Koh ES, Shin HK, Kim DJ. Prognostic value of baseline carcinombryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer. Cancer Biomark. 2018. 22: 55-62. https://doi.org/10.3233/CBM-170885
  4. Cannon GW, Getzenberg RH. Biomarkers for benign prostatic hyperplasia progression. Curr Urol Rep. 2008. 9: 279-283. https://doi.org/10.1007/s11934-008-0049-5
  5. Cao J, Fu Z, Gao L, Wang X, Cheng S, Wang X, Ren H. Evaluation of serum d-dimer, fibrinogen, and ca19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma. World J Surg Oncol. 2017. 15: 48.
  6. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. Ca125 and ovarian cancer: A comprehensive review. Cancers (Basel). 2020. 12.
  7. Chen F, Li J, Qi X, Qi J. Diagnostic value of cyfra 21-1 and carinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease. J Cancer Res Ther. 2018a. 14: S400-S404. https://doi.org/10.4103/0973-1482.174180
  8. Chen ZQ, Huang LS, Zhu B. Assessment of seven clinical tumor markers in diagnosis of non-small-cell lung cancer. Dis Markers. 2018b. 2018: 9845123.
  9. Cheng F, Yuan Q, Yang J, Wang W, Liu H. The prognostic value of serum neuron-specific enolase in traumatic brain injury: Systematic review and meta-analysis. PLoS One. 2014. 9: e106680.
  10. Dauti F, Hjaltalin Jonsson M, Hillarp A, Bentzer P, Schott U. Perioperative changes in pivka-ii. Scand J Clin Lab Invest. 2015. 75: 562-567. https://doi.org/10.3109/00365513.2015.1058521
  11. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis b. Cancer. 1989. 64: 2117-2120. https://doi.org/10.1002/1097-0142(19891115)64:10<2117::AID-CNCR2820641024>3.0.CO;2-7
  12. Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: Ca125, he4, rmi and roma, a review. J Ovarian Res. 2019. 12: 28.
  13. Dong A, Zhang J, Chen X, Ren X, Zhang X. Diagnostic value of progrp for small cell lung cancer in different stages. J Thorac Dis. 2019. 11: 1182-1189.
  14. Duffy MJ. Tumor markers in clinical practice: A review focusing on common solid cancers. Med Princ Pract. 2013. 22: 4-11. https://doi.org/10.1159/000338393
  15. Fahy BN. Follow-up after curative resection of colorectal cancer. Ann Surg Oncol. 2014. 21: 738-746. https://doi.org/10.1245/s10434-013-3255-4
  16. Fukuda I, Yamakado M, Kiyose H. Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services. J Med Syst. 1998. 22: 89-93. https://doi.org/10.1023/A:1022643102208
  17. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965. 121: 439-462. https://doi.org/10.1084/jem.121.3.439
  18. Haythorn MR, Ablin RJ. Prostate-specific antigen testing across the spectrum of prostate cancer. Biomark Med. 2011. 5: 515-526. https://doi.org/10.2217/bmm.11.53
  19. Huang L, Zhou JG, Yao WX, Tian X, Lv SP, Zhang TY, Jin SH, Bai YJ, Ma H. Systematic review and meta-analysis of the efficacy of serum neuron-specific enolase for early small cell lung cancer screening. Oncotarget. 2017. 8: 64358-64372. https://doi.org/10.18632/oncotarget.17825
  20. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001. 5: 145-159.
  21. Kiebish MA, Tekumalla P, Ravipaty S, Dobi A, Srivastava S, Wu W, Patil S, Friss T, Klotz A, Srinivasan A, Cullen J, Rosner IL, Ali A, Laszlo S, Petrovic M, Fleshner N, Garren J, Miller G, Mahaveer Chand N, Rodrigues LO, et al. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia. Sci Rep. 2021. 11: 15052.
  22. Lakemeyer L, Sander S, Wittau M, Henne-Bruns D, Kornmann M, Lemke J. Diagnostic and prognostic value of cea and ca19-9 in colorectal cancer. Diseases. 2021. 9.
  23. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer. 2008. 8: 268-278. https://doi.org/10.1038/nrc2351
  24. Liu F, Kong X, Dou Q, Ye J, Xu D, Shang H, Xu K, Song Y. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites. Ann Hepatol. 2014. 13: 357-363. https://doi.org/10.1016/S1665-2681(19)30865-8
  25. Liu L, Teng J, Zhang L, Cong P, Yao Y, Sun G, Liu Z, Yu T, Liu M. The combination of the tumor markers suggests the histological diagnosis of lung cancer. Biomed Res Int. 2017. 2017: 2013989.
  26. Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers ca19-9 and cea. Ann Clin Biochem. 1998. 35(Pt 1): 99-103. https://doi.org/10.1177/000456329803500113
  27. Matuszczak M, Salagierski M. Diagnostic and prognostic potential of biomarkers cyfra 21.1, ercc1, p53, fgfr3 and tati in bladder cancers. Int J Mol Sci. 2020. 21.
  28. Meng Q, Shi S, Liang C, Xiang J, Liang D, Zhang B, Qin Y, Ji S, Xu W, Xu J, Ni Q, Yu X. Diagnostic accuracy of a ca125-based biomarker panel in patients with pancreatic cancer: A systematic review and meta-analysis. J Cancer. 2017. 8: 3615-3622. https://doi.org/10.7150/jca.18901
  29. Molina R, Escudero JM, Auge JM, Filella X, Foj L, Torne A, Lejarcegui J, Pahisa J. He4 a novel tumour marker for ovarian cancer: Comparison with ca 125 and roma algorithm in patients with gynaecological diseases. Tumour Biol. 2011. 32: 1087-1095. https://doi.org/10.1007/s13277-011-0204-3
  30. Molina R, Filella X, Auge JM. Progrp: A new biomarker for small cell lung cancer. Clin Biochem. 2004. 37: 505-511. https://doi.org/10.1016/j.clinbiochem.2004.05.007
  31. Molina R, Marrades RM, Auge JM, Escudero JM, Vinolas N, Reguart N, Ramirez J, Filella X, Molins L, Agusti A. Assessment of a combined panel of six serum tumor markers for lung cancer. Am J Respir Crit Care Med. 2016. 193: 427-437. https://doi.org/10.1164/rccm.201404-0603oc
  32. Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. The diagnostic and prognostic value of progrp in lung cancer. Anticancer Res. 2009. 29: 4827-4832.
  33. Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y. Diagnostic value of cea and cyfra 21-1 tumor markers in primary lung cancer. Lung Cancer. 2013. 80: 45-49. https://doi.org/10.1016/j.lungcan.2013.01.002
  34. Ran C, Sun J, Qu Y, Long N. Clinical value of mri, serum scca, and ca125 levels in the diagnosis of lymph node metastasis and para-uterine infiltration in cervical cancer. World J Surg Oncol. 2021. 19: 343.
  35. Rao S, Smith DA, Guler E, Kikano EG, Rajdev MA, Yoest JM, Ramaiya NH, Tirumani SH. Past, present, and future of serum tumor markers in management of ovarian cancer: A guide for the radiologist. Radiographics. 2021. 41: 1839-1856. https://doi.org/10.1148/rg.2021210005
  36. Ruibal Morell A. Cea serum levels in non-neoplastic disease. Int J Biol Markers. 1992. 7: 160-166. https://doi.org/10.1177/172460089200700307
  37. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer i: Blood-based markers. Acta Oncol. 2011. 50 Suppl 1: 61-75.
  38. Sokolenko AP, Imyanitov EN. Molecular diagnostics in clinical oncology. Front Mol Biosci. 2018. 5: 76.
  39. Sorensen CG, Karlsson WK, Pommergaard HC, Burcharth J, Rosenberg J. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence - a systematic review. Int J Surg. 2016. 25: 134-144.
  40. Staib L, Link KH, Beger HG. Follow-up in colorectal cancer: Cost-effectiveness analysis of established and novel concepts. Langenbecks Arch Surg. 2000. 385: 412-420. https://doi.org/10.1007/s004230000144
  41. Stenman UH, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin Cancer Biol. 1999. 9: 83-93. https://doi.org/10.1006/scbi.1998.0086
  42. van Heurn LJ, Knipscheer MM, Derikx JPM, van Heurn LWE. Diagnostic accuracy of serum alpha-fetoprotein levels in diagnosing recurrent sacrococcygeal teratoma: A systematic review. J Pediatr Surg. 2020. 55: 1732-1739. https://doi.org/10.1016/j.jpedsurg.2020.03.014
  43. Wang T, Matsuda Y, Seki A, Nonaka K, Kakizaki M, Kaneda D, Takahashi-Fujigasaki J, Murayama S, Arai T. Carbohydrate antigen 19-9-positive gastric adenocarcinoma: Autopsy findings and review of the literature. Case Rep Gastroenterol. 2017a. 11: 545-553. https://doi.org/10.1159/000479223
  44. Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, Shi Y, Zhao X, Jing J. The diagnostic value of serum tumor markers cea, ca19-9, ca125, ca15-3, and tps in metastatic breast cancer. Clin Chim Acta. 2017b. 470: 51-55. https://doi.org/10.1016/j.cca.2017.04.023
  45. Wongkham S, Silsirivanit A. State of serum markers for detection of cholangiocarcinoma. Asian Pac J Cancer Prev. 2012. 13 Suppl: 17-27.
  46. Xu F, Zhang L, He W, Song D, Ji X, Shao J. The diagnostic value of serum pivka-ii alone or in combination with afp in chinese hepatocellular carcinoma patients. Dis Markers. 2021. 2021: 8868370.
  47. Yang Y, Zhang H, Zhang M, Meng Q, Cai L, Zhang Q. Elevation of serum cea and ca15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients. Oncol Lett. 2017. 14: 7549-7556.
  48. Yerushalmi R, Tyldesley S, Kennecke H, Speers C, Woods R, Knight B, Gelmon KA. Tumor markers in metastatic breast cancer subtypes: Frequency of elevation and correlation with outcome. Ann Oncol. 2012. 23: 338-345. https://doi.org/10.1093/annonc/mdr154